Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 27th:Toll Brothers TOL: This company that builds single-family detached and attached home communities carries a Zacks Rank #1 (Strong Buy), and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 12.6% over the last 60 days.Toll Brothers Inc. Price and Consensus Toll Brothers Inc. price-consensus-chart | Toll Brothers Inc. QuoteToll Brothers has a PEG ratio of 0.21 compared with 0.42 for the industry. The company possesses a Growth Score of A.Toll Brothers Inc. PEG Ratio (TTM) Toll Brothers Inc. peg-ratio-ttm | Toll Brothers Inc. QuotePfizer PFE: This company that manufactures, markets, distributes, and sells biopharmaceutical products carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 53.5% over the last 60 days.Pfizer Inc. Price and Consensus Pfizer Inc. price-consensus-chart | Pfizer Inc. QuotePfizer has a PEG ratio of 0.69 compared with 1.68 for the industry. The company possesses a Growth Score of B.Pfizer Inc. PEG Ratio (TTM) Pfizer Inc. peg-ratio-ttm | Pfizer Inc. QuoteMacy's M: This omnichannel retail organization carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.5% over the last 60 days.Macy's, Inc. Price and Consensus Macy's, Inc. price-consensus-chart | Macy's, Inc. QuoteMacy's has a PEG ratio of 0.44 compared with 0.63 for the industry. The company possesses a Growth Score of A.Macy's, Inc. PEG Ratio (TTM) Macy's, Inc. peg-ratio-ttm | Macy's, Inc. QuoteSee the full list of top ranked stocks here.Learn more about the Growth score and how it is calculated here.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Macy's, Inc. (M): Free Stock Analysis Report Toll Brothers Inc. (TOL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research